Bolt Biotherapeutics, Inc. (BOLT)

NASDAQ: BOLT · IEX Real-Time Price · USD
1.51
0.00 (0.00%)
At close: Oct 4, 2022 4:00 PM
1.50
-0.01 (-0.99%)
After-hours: Oct 4, 2022 6:45 PM EDT
0.00%
Market Cap 55.71M
Revenue (ttm) 1.26M
Net Income (ttm) -96.89M
Shares Out 36.89M
EPS (ttm) -2.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 103,875
Open 1.63
Previous Close 1.51
Day's Range 1.50 - 1.66
52-Week Range 1.39 - 14.18
Beta n/a
Analysts Buy
Price Target 6.53 (+332.5%)
Earnings Date Nov 7, 2022

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antib... [Read more...]

Industry Biotechnology
IPO Date Feb 5, 2021
Employees 91
Stock Exchange NASDAQ
Ticker Symbol BOLT
Full Company Profile

Financial Performance

In 2021, BOLT's revenue was $1.26 million, an increase of 445.45% compared to the previous year's $231,000. Losses were -$98.59 million, 62.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price forecast is 6.53, which is an increase of 332.45% from the latest price.

Price Target
$6.53
(332.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of...

1 month ago - GlobeNewsWire

Bolt, Orion-E to build solar plants in Brazil for about $630 million

Energy infrastructure company Orion-E has reached an agreement with energy trader Bolt to build solar photovoltaic plants in Brazil with a combined capacity of 500 megawatts (MW), a company executive sa...

1 month ago - Reuters

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio prioritization and capital allocation strategy e...

1 month ago - GlobeNewsWire

5 Top-Ranked Stocks to Bet Big on Rising P/E Investing

Tap five stocks with increasing P/E ratios to try an out-of-the-box approach.

Other symbols: BKECSVPOOLTITN
3 months ago - Zacks Investment Research

Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present -

4 months ago - GlobeNewsWire

Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

–   BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022

4 months ago - GlobeNewsWire

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Other symbols: ANGNAPLTIKNALABP
4 months ago - Zacks Investment Research

Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine t...

5 months ago - GlobeNewsWire

Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights

REDWOOD CITY, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine t...

6 months ago - GlobeNewsWire

7 Little-Known Penny Stocks That Could Take Off Any Moment

Penny stocks are incredibly risky and should only be considered with speculation funds. Still, these names could swing higher for investors.

Other symbols: BOXLMUXPOWWSHIPWTRH
8 months ago - InvestorPlace

3 Biotech Stocks That Sank: Are Any a Bad-News Buy?

At least one of the three could be in store for better news in the future.

Other symbols: AGLERETA
9 months ago - The Motley Fool

Why Bolt Biotherapeutics Stock Crashed Today

The company announced disappointing interim data from a phase 1/2 study of its lead cancer program.

9 months ago - The Motley Fool

Bolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidate

Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a...

9 months ago - Benzinga

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emer...

Company to continue monotherapy dose-escalation and evaluate weekly dose regimen

9 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Co...

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

10 months ago - GlobeNewsWire

Bolt Biotherapeutics Announces Changes to its Board of Directors

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targ...

10 months ago - GlobeNewsWire

Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer ...

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

10 months ago - GlobeNewsWire

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

–BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021 –Strong cash position of $295.5 million expected t...

10 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer An...

Three SITC presentations highlight the breadth of immuno-oncology strategies from the company's expanding portfolio Three SITC presentations highlight the breadth of immuno-oncology strategies from the ...

1 year ago - GlobeNewsWire

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with...

REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine t...

1 year ago - GlobeNewsWire

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the tar...

1 year ago - GlobeNewsWire

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

SAN FRANCISCO and SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

1 year ago - PRNewsWire

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

1 year ago - GlobeNewsWire

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001...

REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

1 year ago - GlobeNewsWire